How SPMS Differs and Why Therapies Must Adapt

Outline at a glance:
– Section 1: What changes in biology and care goals when MS becomes secondary progressive, and how this shapes research.
– Section 2: Evidence for disease‑modifying therapies (DMTs) in SPMS, with practical caveats on activity status and safety.
– Section 3: Symptom control, rehabilitation, and assistive technologies that move the needle on daily function.
– Section 4: Emerging and experimental strategies, from remyelination to microglial modulation.
– Section 5: Measuring progression in trials and clinics, and using data to guide real‑world choices.

Secondary progressive multiple sclerosis (SPMS) represents a shift from flare‑dominated disease biology to a steadier, smoldering process. Early in the MS journey, much of the damage is tied to immune cells crossing the blood–brain barrier and causing relapses. Over time, inflammation becomes more compartmentalized within the central nervous system, with microglial activation, meningeal aggregates, and diffuse neurodegeneration playing larger roles. The clinical picture follows suit: fewer overt relapses, more gradual worsening of mobility, hand dexterity, cognition, and fatigue. This turning point matters because therapies that excel at quelling relapses may have less impact on disability accrual when relapses fade from the foreground.

Research in SPMS therefore chases two moving targets at once: residual inflammatory activity and progression independent of relapse activity (often termed PIRA). Trials traditionally relied on the Expanded Disability Status Scale (EDSS) and relapse counts, but newer studies incorporate time‑to‑confirmed disability progression over 3–6 months, walking and hand function tests, and cognitive measures. MRI outcomes now emphasize brain and spinal atrophy, slowly expanding lesions, and paramagnetic rim lesions as windows into chronic inflammation. Patient‑reported outcomes and digital mobility metrics help capture what matters day to day, like endurance in a grocery aisle or the reliability of a hand grip.

Because SPMS is heterogeneous, evidence is often “signal‑specific.” A therapy can reduce relapses in “active SPMS” (defined by recent relapses or enhancing lesions) yet show modest effects on long‑term disability. Conversely, interventions that rarely affect relapse counts may still influence atrophy rates or walking decline. Pragmatically, this means:
– Classifying disease activity before choosing or switching a therapy.
– Weighing absolute risk reductions against monitoring burdens and safety profiles.
– Combining disease‑modifying strategies with structured rehabilitation to address disability from multiple angles.

Think of SPMS care as tending embers rather than dousing flames. The heat source is subtler, but targeted air control (anti‑inflammatory therapy), insulation (neuroprotection), and smart architecture (rehab and assistive tech) together can meaningfully change how the fire behaves in the long run.

Disease‑Modifying Therapies in SPMS: What Trials Show

Modern disease‑modifying therapies (DMTs) span several mechanisms: S1P receptor modulators, B‑cell–directed agents, cell trafficking blockers, interferons, immune reconstitution treatments, and older cytotoxic options. In SPMS, evidence hinges on whether disease remains “active.” When relapses or gadolinium‑enhancing lesions persist, relative risk reductions for disability progression and MRI activity tend to be larger; without activity, effects often shrink.

S1P modulators have the most direct randomized data in SPMS. In a large phase 3 study of siponimod, the relative risk of 3‑month confirmed disability progression decreased by roughly one fifth compared with placebo, with greater benefits seen in participants with recent inflammatory activity. The drug also lowered relapse rates and MRI lesion activity. Safety considerations include bradyarrhythmia risk around initiation, liver enzyme elevations, macular changes, and infection susceptibility—hence cardiac screening, ophthalmic checks, and lab monitoring are routine. Fingolimod, an earlier agent in the class, demonstrated relapse control in relapsing MS; in progressive populations, effects on confirmed progression have been less consistent, but some patients with ongoing activity may derive benefit.

B‑cell–directed therapy has robust evidence in relapsing MS and primary progressive disease for certain subgroups. In SPMS specifically, randomized data are more limited, but clinicians sometimes consider this mechanism in active SPMS given its impact on inflammatory drivers. Typical watch‑outs involve infusion reactions, hypogammaglobulinemia over time, and infection risk management, including vaccination planning prior to initiation.

Cell trafficking blockade reduced relapses and MRI activity in relapsing disease. In a dedicated SPMS trial targeting disability progression, the primary endpoint was not met overall, although exploratory signals suggested possible effects on upper limb function in a subset. The agent carries a small but serious risk of opportunistic brain infection, so risk stratification and vigilance are central to decision‑making.

Interferon beta has long‑standing use and can reduce relapses; however, trials in SPMS generally showed limited effects on sustained disability progression, especially in non‑active disease. Flu‑like symptoms, injection‑site reactions, and laboratory monitoring are familiar aspects of its profile. Cladribine, an oral immune reconstitution therapy, produces durable lymphocyte reductions and is effective in highly active relapsing MS; SPMS‑specific data are scarce, but some clinicians consider it in individuals who retain inflammatory activity. Mitoxantrone historically demonstrated benefits in aggressive progressive disease, yet declining use reflects cardiotoxicity, leukemia risk, and cumulative dose limits.

Key practical takeaways:
– Therapy selection is anchored to activity status; “active SPMS” behaves more like relapsing disease, improving the chance of measurable benefit from anti‑inflammatory agents.
– Absolute gains are often modest at the individual level; setting expectations around timelines (12–24 months) and endpoints (walking speed, hand function) is essential.
– Safety stewardship—vaccinations, cancer screening when indicated, and infection prevention—can protect long‑term options.

In short, DMTs in SPMS can matter, especially when activity persists, but they are rarely a solo act. Pairing them with rehabilitation and symptom control makes the clinical impact more tangible.

Symptom Management and Rehabilitation: Turning Gains into Daily Wins

If DMTs reshape the disease course, symptom and function‑focused care shape the day. In SPMS, mobility, fatigue, spasticity, bladder and bowel issues, pain, and cognitive shifts often drive quality of life more than MRI scans. Evidence favors multidisciplinary approaches that blend physical therapy, occupational therapy, speech‑language strategies, psychological support, and judicious pharmacology. The goal is incremental, reproducible wins: smoother transfers, a longer grocery run without stopping, or steadier hand performance on a keyboard.

Mobility and balance: Task‑oriented gait training, resistance work, and aerobic conditioning can improve walking speed and endurance. Trials report meaningful changes in timed walking tests and six‑minute walk distances after structured programs of 8–12 weeks. Balance‑specific regimens—incorporating perturbation exercises and dual‑task practice—reduce falls. Functional electrical stimulation for foot drop can increase walking distance and confidence in uneven terrain. Orthotics and canes or rollators, when fitted well, trade small reductions in pace for large gains in safety and independence.

Spasticity and stiffness: Oral antispasticity agents such as baclofen or tizanidine reduce tone, though sedation and weakness can limit dosing. For focal patterns, botulinum toxin injections paired with stretching and task practice can improve targeted functions like grasp or ankle dorsiflexion. Severe, generalized spasticity sometimes responds to intrathecal baclofen after a screening trial. Practical coaching on stretching frequency, heat sensitivity management, and nighttime positioning adds low‑risk benefits.

Fatigue and cognition: Energy conservation training, graded activity pacing, and cognitive behavioral strategies have the strongest track record for reducing fatigue interference with daily life. Pharmacologic options offer mixed results and should be personalized. Cognitive rehabilitation that trains attention and processing speed can lift performance on everyday tasks; digital exercises are most effective when integrated with real‑world routines and caregiver support.

Bladder, bowel, and sexual health: Antimuscarinic or beta‑3 agonist therapies can ease urgency and frequency, while pelvic floor therapy enhances control and reduces leakage. Intermittent self‑catheterization improves emptying and cuts infection risk when taught carefully. Constipation management relies on fiber, fluid, timed toileting, and, when needed, osmotic laxatives. Open conversations about sexual function enable tailored strategies that improve intimacy and confidence.

Pain and mood: Neuropathic pain responds variably to agents like gabapentin, pregabalin, duloxetine, or tricyclic options; combining medication with desensitization techniques and sleep optimization helps. Depression and anxiety are common and treatable; integrating counseling with exercise and, when indicated, medication correlates with better adherence to rehabilitation and improved outcomes.

Practical notes:
– Small, specific goals beat vague ambitions; measure what matters (stairs climbed, minutes on feet, keyboard accuracy).
– Heat and infection can temporarily worsen symptoms; plan activity and hydration with weather and illness in mind.
– Technology—from ankle‑foot orthoses to voice dictation—multiplies the payoffs of therapy time.

In SPMS, progress often arrives in the form of smoother routines. That texture of daily life is exactly where rehab shines.

Emerging and Experimental Strategies: From Remyelination to Microglia

Beyond established DMTs, research is probing the biology that underpins steady worsening in SPMS: failure of remyelination, mitochondrial stress, and chronic, compartmentalized inflammation. The pipeline spans remyelinating candidates, microglial and B‑cell signaling modulators, neuroprotective antioxidants, stem cell approaches, neuromodulation, and lifestyle‑adjacent interventions. Early‑phase signals are intriguing, but replication and disability‑anchored endpoints remain the hurdle.

Remyelination and repair: Agents aimed at oligodendrocyte differentiation have shown mixed results. An antihistamine with antimuscarinic properties improved visual evoked potential latency in a small optic pathway study, signaling possible remyelination, but disability outcomes and generalizability are not established. Antibodies targeting inhibitory molecules in myelination produced negative or inconclusive results in larger trials. The lesson is sobering yet constructive: physiological markers can move without translating to functional change, so next‑gen studies co‑prioritize meaningful clinical endpoints.

Microglial modulation and kinases: Bruton’s tyrosine kinase (BTK) inhibitors, designed to affect both peripheral B‑cells and CNS‑resident microglia, are being evaluated in progressive phenotypes. Early data show reductions in MRI lesion activity and hints on slowly expanding lesions, but safety signals—especially hepatic or infectious—demand careful dose‑finding and long‑term follow‑up. Other small‑molecule strategies look upstream at inflammasome activity or downstream at oxidative stress.

Neuroprotection: Lipid‑soluble antioxidants and metabolic supports have been tested for impacts on brain atrophy and walking decline. Some small randomized studies in progressive MS suggested slower atrophy rates or functional benefits, while others were neutral; heterogeneity in cohorts and endpoints complicates interpretation. High‑dose biotin drew attention after open‑label improvements were reported in progressive disease, but subsequent randomized trials yielded conflicting or neutral results, tempering enthusiasm and underscoring the need for stratified designs.

Cell‑based therapies: Autologous hematopoietic stem cell transplantation resets immune repertoires and can suppress inflammatory activity; it is studied mainly in highly active relapsing disease and selected progressive cases with activity. Mesenchymal stromal cells, delivered intrathecally or intravenously, have shown safety in small studies and exploratory improvements in visual and functional measures, but definitive, multi‑center trials with disability endpoints are pending.

Neuromodulation and lifestyle: Non‑invasive stimulation techniques (such as transcranial direct current stimulation) show variable effects on fatigue and cognition, with protocol differences likely explaining disparities. Exercise “as medicine” remains promising: resistance and aerobic training may induce neurotrophic changes measurable on imaging, reinforcing behavioral interventions as a biologically relevant therapy. Diet patterns rich in plants, unsaturated fats, and fiber align with cardiometabolic health and may associate with lower disability in observational studies; causation is unproven, but the risk‑benefit ratio is favorable.

Bottom line:
– Signals exist across several fronts, yet durable, disability‑centered benefits must be confirmed in phase 3 trials.
– Biomarkers—slowly expanding lesions, paramagnetic rims, serum neurofilament light—will likely guide who benefits from which approach.
– Safety guardrails must mature alongside efficacy claims to ensure real‑world viability.

Measuring Progress and Making Real‑World Decisions

SPMS research lives and dies by endpoints, and care decisions should borrow that rigor. Traditional anchors include time to 3‑ or 6‑month confirmed disability progression on the EDSS, annualized relapse rate, and T2 lesion burden. Each has blind spots: EDSS overweights ambulation and underweights cognition and upper limb function; relapse rates lose meaning as disease quiets; lesion counts miss the “smolder.” Modern frameworks add:
– PIRA vs. relapse‑associated worsening to separate long‑term drivers from episodic hits.
– Performance measures such as the Timed 25‑Foot Walk, 9‑Hole Peg Test, and Symbol Digit Modalities Test to map legs, hands, and cognition.
– Imaging of atrophy, slowly expanding lesions, and paramagnetic rim lesions to track chronic inflammation and tissue loss.
– Optical coherence tomography to quantify retinal nerve fiber thinning as a proxy for neuroaxonal injury.
– Digital mobility metrics (daily step counts, dwell time on stairs) to reflect life‑embedded function.

For individuals, decision‑making starts with activity status, age, comorbidities, pregnancy plans, and personal priorities. An active SPMS profile (recent relapses or enhancing lesions) may justify escalation to an agent with stronger anti‑inflammatory potency and higher monitoring needs. In non‑active SPMS, expectations shift toward stability and slowing, with emphasis on rehabilitation intensity, fall prevention, and symptomatic optimization. Regardless of path, safety strategy—vaccinations prior to immunotherapy when appropriate, infection risk minimization, cancer screenings, and bone health—protects long‑term resiliency.

Trials and registries feed this loop. Event‑driven designs with longer follow‑up improve power to detect small but meaningful differences in progression. Pragmatic studies and real‑world registries capture adherence, adverse events, and functional outcomes beyond clinic visits. Stratification by biomarkers (e.g., neurofilament light), imaging signatures, or genetic risk may unlock precision approaches that match therapies to dominant mechanisms.

Practical roadmap for the clinic:
– Define goals that map to measurable outcomes (walk time, hand dexterity, cognitive speed).
– Align therapy choice with disease activity and risk tolerance; revisit at 6–12‑month intervals with objective metrics.
– Invest in rehabilitation early; gains compound when practiced daily and reinforced with assistive tech.
– Document and address fatigue, mood, and sleep—these amplify or mute every other intervention.

When research metrics and personal goals line up, progress becomes visible—not always dramatic, but steady enough to matter in the rhythm of everyday life.